Monopar Therapeutics’ (MNPR) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $100.00 price objective on the stock.

Several other equities analysts have also recently commented on the company. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Finally, Morgan Stanley started coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Monopar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR opened at $55.39 on Monday. The firm has a fifty day moving average price of $58.68 and a two-hundred day moving average price of $70.92. Monopar Therapeutics has a one year low of $26.06 and a one year high of $105.00. The company has a market cap of $370.56 million, a price-to-earnings ratio of -30.43 and a beta of 1.64.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). Equities research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in shares of Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after purchasing an additional 30,042 shares in the last quarter. RA Capital Management L.P. raised its holdings in shares of Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after buying an additional 156,000 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Monopar Therapeutics by 79.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock worth $15,274,000 after buying an additional 103,909 shares during the last quarter. Wellington Management Group LLP bought a new stake in Monopar Therapeutics in the 3rd quarter worth approximately $18,904,000. Finally, Siren L.L.C. purchased a new stake in Monopar Therapeutics in the fourth quarter worth approximately $13,863,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics News Roundup

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed a Buy rating on MNPR, providing a straightforward positive catalyst that can support demand from growth-oriented investors. Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR)
• Positive Sentiment: HC Wainwright materially increased Monopar’s long-term earnings outlook — raising FY2029 to $1.79 (from about -$0.07) and projecting FY2030 at $4.38 — and improved FY2027 and FY2028 estimates (less negative). These changes signal the analyst sees meaningful longer?term upside tied to successful clinical/program milestones.
• Neutral Sentiment: HC Wainwright published a full slate of updated forecasts through FY2030 (Q1–Q4 2026 and multi-year projections). Investors should treat these as model-driven scenarios that reflect both near-term risk and long-term optionality rather than confirmed outcomes.
• Negative Sentiment: HC Wainwright cut near-term 2026 estimates across the board: Q1 2026 EPS to ($0.77) from ($0.55), Q2 to ($0.82) from ($0.58), Q3 to ($0.91) from ($0.65), Q4 to ($1.02) from ($0.73), and lowered FY2026 to ($3.53) from ($2.52). These downward revisions highlight bigger near?term cash burn/expense or pushed-out milestones and are a clear negative for short-term earnings expectations.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.